| Document |
Document Title |
|
WO/2021/061823A1 |
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibi...
|
|
WO/2021/058406A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2021/055752A1 |
The disclosure relates to benzoxaborole containing polymers and to methods of using the same to treat metabolic and gastrointestinal disorders.
|
|
WO/2021/055759A1 |
The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.
|
|
WO/2021/049600A1 |
Provided is a pharmaceutical composition that is effective against various β-lactamase-producing bacteria. The present invention provides a pharmaceutical composition characterized by combining: a compound indicated by formula (I) or ...
|
|
WO/2021/049537A1 |
The present invention provides: a three-dimensional control catalyst suitable for the polymerization of a wide range of monomers and used in radical polymerization whereby polymerization that controls both molecular weight (molecular wei...
|
|
WO/2021/049889A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/048044A1 |
The present invention relates to an electronic component comprising a cerium IV complex, a doped semi-conductor matrix material comprising the cerium IV complex and at least one electron donor, the use of the cerium IV complex, especiall...
|
|
WO/2021/049520A1 |
Provided is an injection for boron neutron capture therapy. An injection that is for boron neutron capture therapy and is to be administered by drip infusion. The injection contains p-boronophenylalanine or a pharmacologically acceptable...
|
|
WO/2021/043187A1 |
Provided is a method for preparing a boron salt of a dipeptide of valine-proline. The method uses pyrrolidine boric acid protected by an R1 group and valine protected by an R4 group as the initial raw materials, and avoids the problem of...
|
|
WO/2021/045207A1 |
The present invention relates to a production method for a highly reactive intermediate. The production method includes: preparing an electron-accepting active compound (1); preparing a piezoelectric material (3); and applying mechanical...
|
|
WO/2021/037278A1 |
Provided are an A-D-A conjugated molecule, a preparation method therefor, an organic solar cell, and the use of the A-D-A conjugated molecule in an organic solar cell. The A-D-A conjugated molecule has the following general structure: (I...
|
|
WO/2021/040455A1 |
The present invention relates to a metal-organic framework (MOF) having a three dimensional porous structure and being represented by the chemical formula of [Al8(OH)a(BTC)b(IPA)c(L)d], a preparation method therefor, and a use thereof as...
|
|
WO/2021/036515A1 |
Provided is a method for synthesizing an alkenyl borate compound, the method comprising: dissolving an alkene compound and a borane compound in a solvent to obtain a mixed solution; adding a zirconium catalyst to the mixed solution; in a...
|
|
WO/2021/033530A1 |
This method for producing a radioactive metal complex comprises a step for reacting a radioactive metal with DOTA or a ligand, which is a derivative of DOTA, in a reaction solution to form a radioactive metal complex. The reaction soluti...
|
|
WO/2021/032088A1 |
The present invention relates to a method for preparing a L-erythrobiopterin compound. The L-erythrobiopterin compound has a structure represented by formula (I), and the L-erythrobiopterin compound represented by formula (I) is mainly p...
|
|
WO/2021/025903A1 |
The present disclosure is related to activator compounds represented by: [Ar(E 1 R 1 R 2 H)x(E 2 R 3 R 4)y][QR 5 R 6 R 7 R 8]z In the formula Ar is a C6-C30 aromatic hydrocarbyl group, provided that if Ar is a multicyclic ring, then each...
|
|
WO/2021/026495A1 |
Embodiments of the present disclosure pertain to methods of treating or preventing Alzheimer's disease or symptoms of Alzheimer's disease in a subject by administering to the subject an active agent that includes an adenovirus-36 E4orf1 ...
|
|
WO/2021/021932A1 |
The present invention relates to methods of preparing benzoxaboroles. Benzoxaborole compounds have shown promise as antimicrobial agents, especially against fungal pathogens. The invention also relates to compositions of acyclic alkoxy b...
|
|
WO/2021/020285A1 |
The purpose of the present invention is to provide a cyclic azine compound that exhibits both excellent driving voltage characteristics and excellent current efficiency characteristics. This cyclic azine compound has a specific structu...
|
|
WO/2021/017274A1 |
The present invention provides a thermally activated delayed fluorescent molecular material and a synthesis method therefor, and an organic electroluminescent device. Boron-nitrogen containing thermally activated delayed fluorescent mole...
|
|
WO/2021/021634A1 |
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been di...
|
|
WO/2021/020928A2 |
The present specification relates to a polycyclic compound and an organic light-emitting element comprising same.
|
|
WO/2021/020929A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2021/020931A1 |
The present specification relates to a compound represented by chemical formula 1, and an organic light emitting device comprising same. In chemical formula 1: A and B may be the same or different, each can be an independently substitute...
|
|
WO/2021/015841A1 |
Provided herein are boron-containing compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders.
|
|
WO/2021/013986A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of formula I wherein RI, RII, RIII and RIV are independently from...
|
|
WO/2021/013996A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of formula (I) wherein RI, RII, RIII and RIV are independently fr...
|
|
WO/2021/015020A1 |
A pyrromethene-boron complex according to an embodiment of the present invention is a compound represented by the following formula (1) and having a molecular weight of at least 1,000, wherein at least two of the R1 to R6 in the formula ...
|
|
WO/2021/014023A1 |
The present invention relates to a an organic electroluminescent device comprising at least one light-emitting layer B comprising at least one host material HB, at least one thermally activated delayed fluorescence (TADF) material EB, an...
|
|
WO/2021/013993A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of Formula (I) wherein RI, RII, RIII and RIV is independently fro...
|
|
WO/2021/015417A1 |
The present invention relates to a polycyclic aromatic derivative and an electroluminescent device comprising same. The electroluminescent device according to the present invention comprises a polycyclic aromatic derivative as a dopant c...
|
|
WO/2021/014380A1 |
Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cancer or a respiratory inflammatory disease using the same: (I) wherein R1 is...
|
|
WO/2021/013800A1 |
The invention relates to substituted N-phenyl-N-aminouracils of general formula (I) or salts thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for co...
|
|
WO/2021/015594A1 |
The present invention relates to the following polycyclic aromatic derivative organic light emitting compound, and an organic light emitting device employing same as a dopant compound of a device light emitting layer. The organic light e...
|
|
WO/2021/014001A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of formula (I) wherein RI, RII, RIII and RIV are independently fr...
|
|
WO/2021/010767A1 |
The present specification provides a compound of chemical formula 1, a coating composition including same, and an organic light-emitting device using same.
|
|
WO/2021/010770A1 |
The present invention relates to a boron compound usable in an organic light-emitting device, and an organic light-emitting device comprising same, and more specifically, to a boron compound represented by any one of chemical formula A t...
|
|
WO/2021/011873A1 |
The present invention provides boron-containing isoquinoline compounds as protein kinase-modulating compounds. These compounds are useful as neuroprotective and neuro-regenerative agents for the amelioration of glaucoma and other ocular ...
|
|
WO/2021/008374A1 |
Provided are a novel organic compound and an application thereof, and an organic electroluminescent device using the same, wherein the compound has a structure as shown in the following formula (1-1), (1-2) or (1-3): wherein: Y 1, Y 2 an...
|
|
WO/2021/004391A1 |
Provided are a c-Myc protein inhibitor, and a preparation method therefor and use thereof. The c-Myc protein inhibitor selectively inhibits c-Myc protein. Therefore, the inhibitor can be used for prevention and treatment of diseases rela...
|
|
WO/2021/004585A1 |
The invention relates to a compound of general formula (I) and to an optoelectronic component having a layer system, wherein at least one layer of the layer system comprises at least one compound of general formula (I).
|
|
WO/2021/003501A1 |
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kina...
|
|
WO/2020/259726A1 |
The present invention relates to cyclen based compounds of general formula (I), wherein X is nitrogen and Y, Z are –CH-, or X, Z are –CH- and Y is nitrogen, or X, Y are –CH- and Z is nitrogen; R1 is independently selected from H; C...
|
|
WO/2020/260384A1 |
The present invention relates to novel luminescent lanthanide chelate reporters which are formed from two to three separate lanthanide chelate moieties covalently conjugated to each other to act as an unique labelling reactant, and which...
|
|
WO/2020/264581A1 |
The present disclosure contemplates a boron-containing compound, a composition containing a pesticidal effective amount of that compound dissolved or dispersed in a carrier medium, and a method of reducing, ameliorating, or controlling a...
|
|
WO/2020/255425A1 |
This anti-HBV agent contains a compound represented by general formula (I) or a compound represented by general formula (II), or a salt thereof.
|
|
WO/2020/253352A1 |
Provided in the present invention are a compound or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or a mixture form thereof, or a pharmaceutical salt thereof, and a preparation method therefor and the use thereof. The ...
|
|
WO/2020/252867A1 |
Disclosed is an organic light-emitting compound and an organic light-emitting device containing the compound, wherein the organic light-emitting compound has a structural formula as shown in formula I. Such compounds can be used as an or...
|
|
WO/2020/252679A1 |
Provided is benzoxaborole-based derivatives and their preparation and use. The structural general formula of the derivatives is (I). The derivatives are used for the preparation of a medicament for the prevention and treatment of Pneumon...
|
